Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
0.417
+0.028 (7.15%)
Jun 29, 2026, 11:06 AM EDT - Market open
Evogene Employees
Evogene had 52 employees as of December 31, 2025. The number of employees decreased by 65 or -55.56% compared to the previous year.
Employees
52
Change (1Y)
-65
Growth (1Y)
-55.56%
Revenue / Employee
$35,462
Profits / Employee
-$226,308
Market Cap
4.07M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| GeoVax Labs | 19 |
| FibroBiologics | 15 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Artelo Biosciences | 7 |
| Galmed Pharmaceuticals | 6 |
| Alzamend Neuro | 6 |
| Creative Medical Technology Holdings | 4 |
EVGN News
- 5 days ago - Evogene achieves integration of agentic systems with ChemPass AI platform - TheFly
- 5 days ago - Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization - PRNewsWire
- 13 days ago - Evogene Slides: Company presentation - Filings
- 20 days ago - Evogene to Present Its Pharma Division Achievements at the BIO International Convention - PRNewsWire
- 27 days ago - Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results - GuruFocus
- 27 days ago - Evogene says Phase 1 clinical study of BMC128 met primary endpoint - TheFly
- 27 days ago - Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica - PRNewsWire
- 4 weeks ago - Evogene price target lowered to $2.15 from $2.25 at Alliance Global - TheFly